Solventum (NYSE:SOLV) Reaches New 52-Week High – What’s Next?

Solventum Corporation (NYSE:SOLV) hit a new 52-week high during trading on Monday . The company traded as high as $90.45 and last traded at $90.4460, with a volume of 50878 shares. The stock had previously closed at $89.57.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of analyst reports. BTIG Research boosted their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Mizuho set a $113.00 target price on shares of Solventum in a research report on Thursday, August 6th. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Sandler boosted their price target on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Stifel Nicolaus increased their price target on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.64.

Solventum Stock Up 0.4%

The firm has a fifty day simple moving average of $81.50 and a 200 day simple moving average of $75.25. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market cap of $15.59 billion, a PE ratio of 11.20, a PEG ratio of 1.18 and a beta of 0.60.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period in the prior year, the firm posted $1.69 EPS. The company’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts predict that Solventum Corporation will post 7.22 EPS for the current year.

Hedge Funds Weigh In On Solventum

Hedge funds have recently made changes to their positions in the stock. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Solventum during the second quarter valued at about $150,066,000. US Bancorp DE raised its holdings in shares of Solventum by 4.6% in the 4th quarter. US Bancorp DE now owns 444,540 shares of the company’s stock worth $35,225,000 after purchasing an additional 19,400 shares during the period. Davis Selected Advisers raised its holdings in shares of Solventum by 12.7% in the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after purchasing an additional 702,461 shares during the period. SG Americas Securities LLC lifted its stake in shares of Solventum by 38.4% in the 1st quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock valued at $8,467,000 after purchasing an additional 35,982 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Solventum by 0.6% in the 1st quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock valued at $93,561,000 after purchasing an additional 9,083 shares in the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.